PODD:NSD-Insulet Corporation (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 235.61

Change

0.00 (0.00)%

Market Cap

USD 16.52B

Volume

0.39M

Analyst Target

USD 241.41
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 27.48B
BRKR Bruker Corporation

N/A

USD 8.98B
MASI Masimo Corporation

N/A

USD 7.71B
PRCT Procept Biorobotics Corp

N/A

USD 4.99B
TMDX TransMedics Group Inc

N/A

USD 4.17B
AXNX Axonics Modulation Technologie..

N/A

USD 3.60B
NARI Inari Medical Inc

N/A

USD 2.85B
LIVN LivaNova PLC

N/A

USD 2.80B
QDEL Quidel Corporation

N/A

USD 2.62B
IRTC iRhythm Technologies Inc

N/A

USD 2.37B

ETFs Containing PODD

EDOC:AU BetaShares Digital Health.. 8.61 % 0.00 %

N/A

N/A
EDOG:LSE Global X Telemedicine & D.. 5.40 % 0.00 %

N/A

USD 0.38M
EDOC:LSE Global X Telemedicine & D.. 5.28 % 0.00 %

N/A

USD 3.69M
EDOC Global X Telemedicine & D.. 5.23 % 0.00 %

N/A

USD 0.04B
DDOC:F Global X Telemedicine & D.. 4.93 % 0.00 %

N/A

USD 4.62M
EDOC:SW Global X Telemedicine & D.. 4.91 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 4.67 % 0.00 %

N/A

USD 2.46M
CIB0:XETRA VanEck Bionic Engineering.. 4.44 % 0.00 %

N/A

USD 4.90M
FDOC:LSE Fidelity Digital Health U.. 4.35 % 0.00 %

N/A

USD 3.02M
CURG:LSE VanEck Genomics and Healt.. 4.34 % 0.00 %

N/A

USD 5.12M
GDOC Goldman Sachs ETF Trust 4.25 % 0.00 %

N/A

USD 0.02B
FDHT 4.07 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.04 % 0.00 %

N/A

N/A
CYBG:LSE VanEck Bionic Engineering.. 3.90 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 3.57 % 0.00 %

N/A

N/A
SAGP The Advisorsa Inner Circl.. 2.04 % 0.00 %

N/A

USD 0.04B
2B78:XETRA iShares Healthcare Innova.. 1.77 % 0.00 %

N/A

USD 1.14B
HEAL:SW iShares Healthcare Innova.. 1.72 % 0.00 %

N/A

N/A
EUSA iShares MSCI USA Equal We.. 0.00 % 0.15 %

N/A

USD 0.92B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.18B
SLIM 0.00 % 0.50 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 5.39M
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.59% 51% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.59% 51% F 58% F
Trailing 12 Months  
Capital Gain 44.92% 55% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.92% 55% F 71% C-
Trailing 5 Years  
Capital Gain 62.70% 75% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.70% 75% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 5.06% 47% F 53% F
Dividend Return 5.06% 47% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.88% 83% B 58% F
Risk Adjusted Return 15.40% 65% D 48% F
Market Capitalization 16.52B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.